System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Research Support, Non-U.S. Gov't Epublish 42 citations

PubMed: 35851597 DOI: 10.1038/s41467-022-31839-7

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil.

Nat Commun 13(1):4154

Authors: Thiago Cerqueira-Silva, Vinicius de Araujo Oliveira, Enny S Paixão, Juracy Bertoldo Júnior, Gerson O Penna, Guilherme L Werneck, Neil Pearce, Maurício L Barreto, Viviane S Boaventura, Manoel Barral-Netto

Affiliations

  • LIB and LEITV Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil.
  • Universidade Federal da Bahia, Salvador, Bahia, Brazil.
  • Center for Data and Knowledge Integration for Health (CIDACS), Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil.
  • London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
  • Núcleo de Medicina Tropical, Universidade de Brasília. Escola Fiocruz de Governo, Fiocruz, DF, Brazil.
  • Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
  • LIB and LEITV Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil.
  • Universidade Federal da Bahia, Salvador, Bahia, Brazil.

Abstract

To date, no information has been published on the effectiveness of inactivated whole-virus COVID-19 vaccines plus heterologous booster against symptomatic infection and severe outcomes (hospitalization or death) during the dominance of the SARS-CoV-2 Omicron variant period. We evaluated the vaccine effectiveness (VE) of CoronaVac plus BNT162b2 booster during the period of dominance of the Omicron variant in Brazil (January to April 2022). Using a test-negative design, we analysed data for 2,471,576 individuals tested during the Omicron variant's dominant period using a nationally linked database from Brazil. Compared to unvaccinated, vaccinees maintained protection against severe outcomes, with an estimated VE of 84.1% (95% CI:83.2-84.9) at more than 120 days after BNT162b2 booster. Furthermore, while we detected a high level of protection against severe outcomes for individuals up to 79 years old, waning was observed for individuals aged ≥80 years, with VE decreasing from 81.3% (95% CI:77.9-84.2) at 31-60 days to 72.9% (95% CI:70.6-75.1) at 120 days or more after the booster dose. However, no significant protection against symptomatic infection was observed at this time period. In conclusion, except for individuals aged ≥80 years, CoronaVac plus a BNT162b2 booster dose offered high and durable protection against severe outcomes due to Omicron.

MeSH

Biological Science Disciplines, Infections, Aged, Covid-19 Vaccines

Cited by